Back to
Dr Melissa Kelly

Dr Melissa Kelly

Conjoint Lecturer

2019: Fellow, Australasian Chapter of Sexual Health Medicine (FAChSHM)

2017: Fellow, Royal Australasian College of Physicians (FRACP) Infectious Diseases

2015: Masters in Public Health & Tropical Medicine , James Cook University, Townsville, QLD

2009: Bachelor of Medicine with Distinction, University of Newcastle, Callaghan, NSW

2004: Bachelor of Nursing, ACU National, North Sydney, NSW

Medicine & Health
School of Population Health

Dr Mel Kelly is a staff specialist in Infectious Diseases and Sexual Health Medicine at The Albion Centre and the Prince of Wales Hospital. Her clinical and research interests include HIV and Viral hepatitis, transgender health, novel antibiotics in the context of STIs and the provision of optimal healthcare to the LGBTQ community.

She is the Medical lead for the t150 transgender health clinic, providing integrated sexual health care and hormone therapy for transgender and gender diverse clients
Phone
+612-9332-9600
E-mail
melissa.kelly@health.nsw.gov.au
Location
The Albion Centre
  • Journal articles | 2024
    Begley K; Smith D; Wand H; Chan D; Furner V; Kelly ML; McGrath P; Hennessy R; Price A; Purnomo L; Bowden BH; Bulsara SM, 2024, '“How well do we know our patients?”: Further validation of a complexity rating scale for HIV', International Journal of STD and AIDS, 35, pp. 1112 - 1119, http://dx.doi.org/10.1177/09564624241279604
    Journal articles | 2017
    Burston J; Adhikari S; Hayen A; Doolan H; Kelly ML; Fu K; Jensen TO; Konecny P, 2017, 'A Role for Antimicrobial Stewardship in Clinical Sepsis Pathways: A Prospective Interventional Study', Infection Control and Hospital Epidemiology, 38, pp. 1032 - 1038, http://dx.doi.org/10.1017/ice.2017.139
    Journal articles | 2016
    Kelly M; Stevens R; Konecny P, 2016, 'Lomentospora prolificans endocarditis - case report and literature review', BMC Infectious Diseases, 16, pp. 36, http://dx.doi.org/10.1186/s12879-016-1372-y

Site PI for the following clinical trials

1. REACH study – Research Evaluating Anal Cancer with HPV in HIV positive populations

2. GSK EAGLE 1 – Gepoticidin in uncomplicated urethral gonorrhoea

3. GoLoCypro – Defining correct dose of cyproterone in transgender women